Jackson Wealth Management LLC Sells 41,939 Shares of Boston Scientific Corporation $BSX

Jackson Wealth Management LLC lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 88.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,306 shares of the medical equipment provider’s stock after selling 41,939 shares during the period. Jackson Wealth Management LLC’s holdings in Boston Scientific were worth $226,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of BSX. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $26,000. Sfam LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Finally, Cresta Advisors Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $33,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research report on Wednesday, July 29th. Mizuho decreased their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Barclays lowered their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Stock Performance

Shares of BSX opened at $48.35 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The firm has a market capitalization of $70.07 billion, a P/E ratio of 19.57, a PEG ratio of 1.02 and a beta of 0.56. The business has a fifty day moving average of $46.65 and a 200 day moving average of $56.35.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock worth $9,385,210 in the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.